T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

CAR-T Cell Toxicity and Safety Profiles

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Researchers uncover immune loop driving Sjögren's disease progression

Sjögren's disease is a widespread chronic autoimmune disorder that attacks the body's own glands, yet its underlying disease mechanisms remain poorly understood.

10 Jun 2026

Laverock Therapeutics reports key oncology research milestones

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications.

From Laverock Therapeutics 10 Jun 2026

AI-designed molecular switch uses caffeine to control engineered cells

For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines.

8 Jun 2026

Defective HIV copies explain persistent viral traces during treatment

Antiretroviral drugs for HIV infection have enabled most people living with the virus to live long and healthy lives.

8 Jun 2026

Review highlights TIGIT as a promising second-generation immunotherapy target

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

5 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

Cross-reactive T cells target measles and dangerous Nipah viruses

T cells are some of the immune system's most important warriors. They can stop tumor growth and even fight off severe infections.

2 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

New advances improve prevention and treatment of HPV-related cancers

A new review article is drawing attention to the growing global impact of human papillomavirus (HPV) and the rapid progress in vaccines and therapeutic strategies aimed at reducing the burden of cervical and non-cervical cancers.

24 May 2026

Mitochondrial checkpoint enables dendritic cells to activate T lymphocytes against viruses, tumors

A study led by researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has identified a mitochondrial "checkpoint" that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumors.

22 May 2026

New vaccine approach targets broad protection against arenavirus infections

Scientists at La Jolla Institute for Immunology (LJI) have discovered that combining key vaccine ingredients could give the body the tools it needs to fight the entire family of arenaviruses with a single vaccine.

21 May 2026

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

21 May 2026

New mRNA vaccine strategy dramatically amplifies cancer-fighting T cells

Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more powerful cancer vaccines and stronger protection against infectious diseases.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026